TNFRSF8 Specific Neutra™ Antibody Products
Product listTNFRSF8 is expressed by activated T and B cells but not in resting ones and is a member of the TNF-receptor superfamily. Interaction between TNFRSF8 with TRAF2 and TRAF5 mediates signal transduction, activating the NF-κB downstream pathway. Functionally, TNFRSF8 constrains the proliferative capacity of autoreactive CD8+ T cells, serving as a positive regulator of apoptosis to safeguard against autoimmunity.
Its Gene ID: 943, UniProtKB ID: P28908, and OMIM ID: 153243.
Pathways of TNFRSF8
TNFRSF8, alias CD30, is specifically expressed in certain hematopoietic malignancies, such as Hodgkin lymphoma. TNFRSF8 belongs to the tumor necrosis factor receptor superfamily and orchestrates its effects via various signaling pathways, collectively imparting a survival advantage to cells with upregulated TNFRSF8. Stimulation of the TNFRSF8 molecule induces trimerization, leading to signal mediation through TRAF and activation of the NF-κB pathway. Additionally, TNFRSF8 ligation triggers signaling through MAPK pathways, which offer diverse pro-survival and anti-apoptotic benefits in neoplastic cells. A positive feedback loop is evident between the nuclear transcription factor JunB and the MAPK/ERK pathway, contributing not only to the upregulation of TNFRSF8 expression but also to cell survival.
Fig.1 Diverse signaling pathways mediated by TNFRSF8 confer a survival advantage for TNFRSF8 to regulate expressed cells.1
TNFRSF8 Antibodies in Therapeutics for Disorders
In recent years, the variable expression of TNFRSF8 on both malignant lymphoid and normal cells has piqued scientific interest. Researchers are delving into TNFRSF8 as a tumor target, aiming to comprehend its role in lymphomagenesis through anti-apoptotic mechanisms, the pathogenesis of TNFRSF8 upregulation, and its impact on cell survival.
- Assessing therapeutic decisions in peripheral T-cell lymphomas with anti-TNFRSF8 antibody
The anti-TNFRSF8 antibody serves as a common tool for assessing TNFRSF8 expression in tissue specimens, exhibiting a strong correlation between immunohistochemical protein expression and specific mRNA levels. The determination of TNFRSF8 status plays a pivotal role in therapeutic decision-making for peripheral T-cell lymphomas. Immunohistochemistry (IHC) proves to be highly reliable for evaluating TNFRSF8 expression, uncovering heterogeneous TNFRSF8 expression across and within entities, significantly associated with large tumor cell size. IHC emerges as a valuable clinical tool for assessing TNFRSF8 expression in PTCLs, and Creative Biolabs provides the Anti-TNFRSF8 Neutralizing Antibody (V3S-0522-YC699), Recombinant Anti-TNFRSF8 Antibody (V3S-0522-YC6604) tailored for IHC applications.
- Anti-TNFRSF8 antibody therapy preclinical studies
TNFRSF8 serves as a tumor marker present on specific cells, including certain immune and cancer cells. The advent of humanized anti-TNFRSF8 monoclonal antibodies (mAbs) has paved the way for immunotherapy clinical trials. Murine anti-TNFRSF8 mAbs have demonstrated tumor growth arrest or regression in an ALCL xenograft model, enhancing disease-free survival rates in xenograft mice. Targeting TNFRSF8 has shown promise in treating TNFRSF8-positive lymphomas, with ongoing research exploring its potential use in autoimmune disorders. Although the effectiveness of bare anti-TNFRSF8 antibodies was limited, the emergence of an antibody-drug conjugate has reignited interest in TNFRSF8 as a viable tumor target. It stands out as one of the first drugs to significantly improve survival in patients with TNFRSF8+ lymphomas. Creative Biolabs offers high-purity Recombinant Anti-TNFRSF8 Antibody (V3S-0622-YC2698) in multiple formats for in vivo and in vitro assays.
Fig.2 TNFRSF8(CD30) CAR T cells xenograft tumor suppression in vivo.2
Creative Biolabs offers a selection of more than 20 anti-TNFRSF8 antibody products. These antibodies find application in research focused on therapies for lymphoma and other diseases. Additionally, customization options are available for TNFRSF8-based bispecific antibodies.
REFERENCES
- Van der Weyden, C. A., et al. "Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions." Blood cancer journal 7.9 (2017): e603-e603.
- Wu, Yang, et al. "A new immunotherapy strategy targeted CD30 in peripheral T-cell lymphomas: CAR-modified T-cell therapy based on CD30 mAb." Cancer Gene Therapy 29.2 (2022): 167-177.
